跨导管三门干预:当前的设备和临床证据
Xiaoping Ning1, Hongjie Xu1, Jingyi Cao1
1Department of Cardiovascular Surgery, Changhai Hospital Affiliated to the Naval Medical University, Shanghai, China.
Journal of cardiology
|April 7, 2024
概括
三管吐 (TR) 是常见的,与糟糕的结果有关,但未得到充分治疗. 至少侵入性跨导管三管干预为重症TR患者提供了有希望的新希望.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 膜心脏疾病 膜心脏疾病
背景情况:
- 三回 (TR) 是一种常见的膜心脏病,通常诊断为晚期,意味着晚期心力衰竭,预后不佳.
- 尽管与死亡率有关,但TR仍然严重治疗不足,目前药物或手术选择的生存益处有限.
- 隔离的三门手术带来了高死亡率,突出显示了对少入侵治疗方法的急需.
研究的目的:
- 为了提供一个全面的和当前的跨导管三门干预的审查.
- 总结这些新疗法的现有临床证据.
主要方法:
- 对跨导管三门干预措施的当前文献的综述.
- 对各种跨导管技术的临床结果和证据的分析.
主要成果:
- 透导管三门干预正在成为传统手术的不那么侵入性的替代方案.
- 这些新型疗法在重症TR患者中表现出有希望的初始结果.
- 该审查整合了支持这些干预措施的最新临床证据.
结论:
- 有迫切的临床需要有效的,不那么侵入性治疗三管吐.
- 跨导管三门干预措施代表了重大进步,为改善患者结果提供了希望.
- 持续的研究和临床评估对于进一步确定这些疗法的作用至关重要.
相关概念视频
Cardiac Catheterization IV: Nursing Management
Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


